Please Wait.....
Report
Global Generic Injectables Market Report and Forecast 2023-2031
Market Report I 2023-05-04 I 147 Pages I EMR Inc.
Global Generic Injectables Market Report and Forecast 2023-2031
Global Generic Injectables Market Outlook:
The global generic injectables market value was USD 101.3 billion in 2022, driven by the increasing demand for affordable healthcare across the globe. The market size is anticipated to grow at a CAGR of 13% during the forecast period of 2023-2031 to achieve a value of USD 305.5 billion by 2031.
Introduction
Generic injectables refer to pharmaceutical products that are identical or bioequivalent to brand-name injectable drugs but are marketed under their generic names. These medications are typically administered via injection, either intravenously, intramuscularly, or subcutaneously. Generic injectables offer cost-effective alternatives to brand-name drugs, providing healthcare providers and patients with more affordable treatment options without compromising quality or safety.
Key Trends in the Generic Injectables Market
Some key trends involved in the generic injectables market are as follows:
- Increasing Demand for Affordable Healthcare: The rising cost of healthcare has led to a growing demand for affordable treatment options, including generic injectables. Healthcare providers and payers are actively seeking cost-saving measures, and the use of generic injectables offers significant savings without compromising patient care.
- Patent Expirations and Market Opportunities: The expiration of patents for several widely-used injectable drugs has opened doors for generic manufacturers to enter the market. This has led to increased competition, reduced prices, and expanded access to essential medications.
- Government Initiatives and Regulatory Support: Governments worldwide are implementing policies and initiatives to promote the use of generic medications, including injectables. These efforts aim to increase access to affordable healthcare and reduce healthcare expenditure. Regulatory agencies also play a vital role by establishing guidelines and standards for the approval and quality assurance of generic injectables.
- Technological Advancements in Manufacturing: Advancements in manufacturing technologies have improved the efficiency and quality of generic injectable production. Advanced manufacturing techniques, such as lyophilization and aseptic processing, ensure the stability, safety, and sterility of generic injectables.
- Expansion of Therapeutic Areas: The range of therapeutic areas covered by generic injectables is expanding. While they have traditionally been associated with essential medications like antibiotics and analgesics, generic injectables are now available for a broader range of therapies, including oncology, critical care, cardiovascular, and neurology.
- Collaboration and Partnerships: Collaboration between generic pharmaceutical companies, contract manufacturers, and healthcare providers is becoming increasingly common. Such partnerships aim to ensure a stable supply of quality generic injectables and improve patient access to affordable medications.
- Rising Demand for Biologics and Biosimilars: The growing demand for biologic drugs has paved the way for the development of biosimilars, which are highly similar but not identical to the original biologic drugs. Biosimilar injectables offer cost savings and expanded treatment options, contributing to the evolving landscape of generic injectables.
Generic Injectables Market Segmentations
Market Breakup by Product Type
- Monoclonal Antibodies
- Immunoglobulin
- Cytokines
- Insulin
- Peptide Hormones
- Blood Factors
- Vaccines
- Chemotherapy Agents
- Small Molecules Antibiotics
- Others
Market Breakup by Molecule Type
- Large Molecules
- Small Molecules
Market Breakup by Application
- Oncology
- Infections Diseases
- Diabetes
- Blood Disorders
- Hormonal Disorders
- Musculoskeletal Disorders
- CNS Diseases
- Pain Management
- Cardiovascular Diseases
- Others
Market Breakup by Route of Administration
- Intramuscular
- Intravenous
- Subcutaneous
Market Breakup by Distribution Channel
- Drug Store
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Generic Injectables Market Scenario
The market for generic injectables is a rapidly growing segment within the pharmaceutical industry. Generic injectables are cost-effective alternatives to brand-name injectable drugs, offering healthcare providers and patients more affordable treatment options without compromising quality or safety.
The market is driven by several factors, including the increasing demand for affordable healthcare solutions, the expiration of patents for widely-used injectable drugs, and government initiatives promoting the use of generic medications. Healthcare providers and payers are actively seeking cost-saving measures, and generic injectables provide significant savings without compromising patient care.
Overall, the market for generic injectables is driven by the increasing demand for affordable healthcare, patent expirations, government initiatives, technological advancements, therapeutic expansion, and collaboration. As the demand for cost-effective injectable medications continues to rise, the market for generic injectables is expected to grow, providing healthcare providers and patients with more accessible treatment options.
Generic Injectables Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Abbott
- B.D.
- Novartis AG
- Pfizer Inc.
- Baxter
- Gerresheimer AG
- Germany
- AstraZeneca
- Terumo Medical Corporation
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Schott AG
- Sanofi
- Johnson & Johnson Private Limited
- Mylan N.V.
- West Pharmaceutical Services, Inc.
- SHL Medical AG
- Insulet Corporation
- E3D Elcam
- Drug Delivery Devices
- Ypsomed AG
- AbbVie Inc.
- Novo Nordisk A/S
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Generics Injectable Market Overview
3.1 Global Generics Injectable Market Historical Value (2016-2022)
3.2 Global Generics Injectable Market Forecast Value (2023-2031)
4 Global Generics Injectable Market Landscape
4.1 Global Generics Injectable Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Generics Injectable Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Applications
4.2.3 Analysis by Distribution Channel
5 Global Generics Injectable Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Generics Injectable Market Segmentation
6.1 Global Generics Injectable Market by Product Type
6.1.1 Market Overview
6.1.2 Monoclonal Antibodies
6.1.3 Immunoglobulin
6.1.4 Cytokines
6.1.5 Insulin
6.1.6 Peptide Hormones
6.1.7 Blood Factors
6.1.8 Vaccines
6.1.9 Chemotherapy Agents
6.1.10 Small Molecules Antibiotics
6.1.11 Others
6.2 Global Generics Injectable Market by Molecule Type
6.2.1 Market Overview
6.2.2 Large Molecules
6.2.3 Small Molecules
6.3 Global Generics Injectable Market by Application
6.3.1 Market Overview
6.3.2 Oncology
6.3.3 Infections Diseases
6.3.4 Diabetes
6.3.5 Blood Disorders
6.3.6 Hormonal Disorders
6.3.7 Musculoskeletal Disorders
6.3.8 CNS Diseases
6.3.9 Pain Management
6.3.10 Cardiovascular Diseases
6.3.11 Others
6.4 Global Generics Injectable Market by Route of Administration
6.4.1 Market Overview
6.4.2 Intramuscular
6.4.3 Intravenous
6.4.4 Subcutaneous
6.5 Global Generics Injectable Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Drug Store
6.5.3 Hospital Pharmacies
6.5.4 Online Pharmacies
6.5.5 Retail Pharmacies
6.6 Global Generics Injectable Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Generics Injectable Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Generics Injectable Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Generics Injectable Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Generics Injectable Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Generics Injectable Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Abbott
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 B.D.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Novartis AG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Pfizer Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Baxter
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Gerresheimer AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Germany
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 AstraZeneca
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Terumo Medical Corporation
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Teva Pharmaceutical Industries Ltd.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Eli Lilly and Company
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Schott AG
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Sanofi
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Johnson & Johnson Private Limited
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Mylan N.V.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 West Pharmaceutical Services, Inc.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 SHL Medical AG
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 Insulet Corporation
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 E3D Elcam
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 Drug Delivery Devices
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
17.21 Ypsomed AG
17.21.1 Financial Analysis
17.21.2 Product Portfolio
17.21.3 Demographic Reach and Achievements
17.21.4 Mergers and Acquisitions
17.21.5 Certifications
17.22 AbbVie Inc.
17.22.1 Financial Analysis
17.22.2 Product Portfolio
17.22.3 Demographic Reach and Achievements
17.22.4 Mergers and Acquisitions
17.22.5 Certifications
17.23 Novo Nordisk A/S
17.23.1 Financial Analysis
17.23.2 Product Portfolio
17.23.3 Demographic Reach and Achievements
17.23.4 Mergers and Acquisitions
17.23.5 Certifications
18 Global Generics Injectable Market- Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Pricing Models and Strategies (Additional Insight)
21.1 Overview
21.2 Cost Model
21.2.1 Manufacturing Cost Analysis
21.2.2 Procurement Cost Analysis
21.2.3 Clinical Trial Cost Factors
21.3 Pricing Strategies
21.3.1 Competitor Pricing Analysis
21.3.2 Key Assessment of Product Attributes
21.3.3 Pricing Benchmark
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security